Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
O14672
UPID:
ADA10_HUMAN
Alternative names:
CDw156; Kuzbanian protein homolog; Mammalian disintegrin-metalloprotease
Alternative UPACC:
O14672; B4DU28; Q10742; Q92650
Background:
Disintegrin and metalloproteinase domain-containing protein 10, also known as ADAM10, plays a pivotal role in cellular processes including proteolytic release of cell-surface proteins and cleavage of amyloid precursor protein (APP). Its activity is crucial for the development and maturation of various tissues, including the vasculature and the nervous system. ADAM10's involvement in cleaving cell adhesion molecules and cytokine receptors underscores its multifaceted role in biological systems.
Therapeutic significance:
ADAM10's link to diseases such as Reticulate acropigmentation of Kitamura and Alzheimer disease 18 highlights its potential as a therapeutic target. Its role in the proteolytic processing of APP and contribution to the amyloidogenic pathway suggest that modulating ADAM10 activity could offer new avenues for treating Alzheimer's disease. Understanding the role of ADAM10 could open doors to potential therapeutic strategies for these conditions.